Journal Article Summary
The article investigates the impact of combined hormone therapy using dehydroepiandrosterone (DHEA) and a combined oral contraceptive (COC) on bone health in young women with anorexia nervosa (AN). This topic is significant because individuals with AN often experience low estrogen levels, which can lead to decreased bone mineral density (BMD) and an increased risk of fractures and osteoporosis. Understanding effective treatments to preserve skeletal health during critical growth periods in adolescence is essential, as bone mass acquisition is vital for long-term skeletal health.
In this study, 94 young women aged 13 to 27 with AN were randomly assigned to receive either the DHEA and COC combination or a placebo for 18 months. The researchers measured changes in bone mineral density and bone turnover markers at multiple points throughout the study. The results indicated that those receiving the DHEA and COC maintained their bone density, while those on placebo experienced a decline. Additionally, the treatment did not result in significant adverse effects, suggesting it is a safe option for this population.
However, the study has limitations, including a high dropout rate and a sample that may not represent all adolescents with AN, as they were generally less severely malnourished. Patients and caregivers should discuss these findings with healthcare professionals, especially regarding the potential benefits and risks of hormone therapy in managing bone health in young women with AN. It is crucial to consider this treatment as part of a comprehensive approach to addressing the nutritional and psychological aspects of the disorder.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- DiVasta Amy D., Feldman Henry A., Giancaterino Courtney, Rosen Clifford J., LeBoff Meryl S., Gordon Catherine M.. The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa. Metabolism: clinical and experimental 2012. DOI: 10.1016/j.metabol.2011.11.016. PMID: 22257645. PMCID: PMC3465078.
Featured Pill Pals Product
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) --- Perrigo --- Over The Counter
OPill (O-Pill) Norgestrel Tablets 0.075 mg Daily Oral Contraceptive (Birth Control) — Perrigo — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
